Glucose control before, during, and after orthotropic heart transplantation presents unique challenges. The presence of advanced heart failure contradicts the use of oral metformin and thiozolidinediones (TZDs). The benefit of insulin has been questioned, and recent investigations question the degree of glycemic control in the ICU.1 Scant published data report on the efficacy of oral hypoglycemics on graft function and survival. The purpose of this summary is to present our approach to patients either listed for or undergoing heart transplantation at The Methodist Hospital.

" /> Glucose control before, during, and after orthotropic heart transplantation presents unique challenges. The presence of advanced heart failure contradicts the use of oral metformin and thiozolidinediones (TZDs). The benefit of insulin has been questioned, and recent investigations question the degree of glycemic control in the ICU.1 Scant published data report on the efficacy of oral hypoglycemics on graft function and survival. The purpose of this summary is to present our approach to patients either listed for or undergoing heart transplantation at The Methodist Hospital.

"> Article Full Text – Methodist Journal
Methodist Journal

IN THIS ISSUE

Lipids and Lipoproteins

Vol 15, Issue 1 (2019)


FEATURED GUEST EDITOR

ISSUE INTRO

Lipids and Cardiovascular Disease: Putting it All Together

See More
RECOGNITIONS

Guest Editors Henry Pownall and Antonio Gotto Offer Insight and Expertise on the topic of Lipids and Cardiovascular Disease

See More

REVIEW ARTICLES See More

Cholesterol: Can’t Live With It, Can’t Live Without It

How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines

Statins: Then and Now

Poststatin Lipid Therapeutics: A Review

HDL and Reverse Cholesterol Transport Biomarkers

Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability

High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes

Gene Delivery in Lipid Research and Therapies

CASE REPORTS See More

Device-Related Thrombus: A Reason for Concern?

Retained Coronary Balloon Requiring Emergent Open Surgical Retrieval: An Uncommon Complication Requiring Individualized Management Strategies

Loperamide Mimicking Brugada Pattern

Reversed Pulsus Paradoxus in Right Ventricular Failure

MUSEUM OF HMH MULTIMODALITY IMAGING CENTER See More

Transcatheter Embolization of a Persistent Vertical Vein: A Rare Cause of Left-to-Right Shunt and Right-Sided Heart Failure

CLINICAL PERSPECTIVES See More

EXCERPTA

Talking Statins with Antonio Gotto

POINTS TO REMEMBER

Lipids and Renal Disease

EXCERPTA

Addressing the Feedback Loop Between Depression, Diabetes, and Cardiovascular Disease

POINTS TO REMEMBER

The Kidney as an Endocrine Organ

EDITORIALS

Addressing the Underrepresentation of Women in Cardiology through Tangible Opportunities for Mentorship and Leadership

Vol 5, Issue 3 (2009)

Article Full Text

REVIEW ARTICLES

Glucose Management, Heart Failure And Transplantation

Jump to:
Article Citation:

Jerry Estep (2009) Percutaneous Device Therapy To Prevent And Treat Acute Decompensated Heart Failure. Methodist DeBakey Cardiovascular Journal: July 2009, Vol. 5, No. 3, pp. 16-25.

doi: https://doi.org/10.14797/mdcj-5-3-12

Abstract

Glucose control before, during, and after orthotropic heart transplantation presents unique challenges. The presence of advanced heart failure contradicts the use of oral metformin and thiozolidinediones (TZDs). The benefit of insulin has been questioned, and recent investigations question the degree of glycemic control in the ICU.1 Scant published data report on the efficacy of oral hypoglycemics on graft function and survival. The purpose of this summary is to present our approach to patients either listed for or undergoing heart transplantation at The Methodist Hospital.

Keywords
glucose , heart transplant , heart failure , insulin , glycemic control

Add Comments

Please login to dialogue with author.

Comments